Skip to content

Comparison of Transcutaneous Vs End-tidal CO2 Pressure Measurements in Hyperventilation Syndrome Diagnosis

Transcutaneous Carbon Dioxide Pressure (tcPCO2) Monitoring Vs End-tidal Partial Pressure Carbon Dioxide (PetCO2) Measurement in the Diagnosis of Hyperventilation Syndrome (HVS) (TCvsPETCO2 )

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03614806
Acronym
TCvsPETCO2
Enrollment
14
Registered
2018-08-03
Start date
2017-12-21
Completion date
2018-02-15
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alkalosis, Respiratory, Hyperventilation, Hyperventilation Syndrome, Hypocapnia

Brief summary

Hyper Ventilation Syndrome is a frequent disease affecting adults whose diagnosis is often belated or even unrecognized due to the lack of gold standard criteria. Its diagnosis currently relies on the Nijmegen score associated with a PetCO2 assesment using a hyperventilation provocation test. Correlation between Nijmegen Questionnaire scores and PetCO2 appears highly variable. PtcCO2 monitoring is a noninvasive alternative method providing a continuous estimation of arterial CO2 pressure (PaCO2) which could represent an advantageous alternative to PetCO2 measurements. Several reports have demonstrated that PtcCO2 monitoring reflects more faithfully PaCO2 than PetCO2, no study have evaluated its value in this indication. The primary aim of the study is to compare the diagnostic value of PtcPCO2 monitoring with PetCO2, the method currently used. Included patient will be invited to fill in the Nijmegen questionnaire and an ambient air gas measurement will be performed. PtcCO2 (mmHg) will be simultaneously measured during hyperventilation test. Nijmegen score signs reproduced by the test will be analysed. HVS diagnosis will be assessed by usual criteria (PetCO2 \<30 mmHg at the end of hyperventilation test or under the PetCO2 value at rest, Nijmegen score\> 23). PtcCO2 data will be blinded interpreted later. We will compare if PetCO2 and PtcCO2 leads to the same diagnosis or not.

Detailed description

Primary Goal: Show that the use of either of the two pCO2 measurements leads to the same diagnostic conclusion in HVS diagnosis with a likelihood greater than 80 %. Secondary Outcome Measures : Evaluate the correlation between PtcCO2 and PtcCO2 measurements Evaluate tolerance to the hyperventilation test Inclusion Criteria : 1. The patient must have reached the age of the civil majority (≥ 18 yo) 2. All patients refered to the Physiology department of Rouen University Hospital, France, for an hyperventilation test 3. The patient must be a member or beneficiary of a health insurance program 4. The patient must have given his / her free and informed consent and signed the consent Exclusion Criteria : 1. Sepsis 2. Hypercapnia (PaCO2 \> 50mmHg) 3. Patient treated by long-term oxygen therapy 4. Subjects under judicial protection, or adults under any kind of guardianship or under judicial control 5. Pregnancy or breastfeeding women 6. Electrolytic unbalance 7. Hyperthyroidism 8. Neurological disease 9. Probability of drug-induced hyperventilation (progestagens , aspirin, beta agonists)

Interventions

DIAGNOSTIC_TESTSimultaneous Transcutaneous and End-tidal CO2 measurements

Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

open label study prospective

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. The patient must have reached the age of the civil majority (≥ 18 yo) 2. All patients refered to the Physiology department of Rouen University Hospital, France, for an hyperventilation test 3. The patient must be a member or beneficiary of a health insurance program 4. The patient must have given his / her free and informed consent and signed the consent

Exclusion criteria

1. Sepsis 2. Hypercapnia (PaCO2 \> 50mmHg) 3. Patient treated by long-term oxygen therapy 4. Subjects under judicial protection, or adults under any kind of guardianship or under judicial control 5. Pregnancy or breastfeeding women 6. Electrolytic unbalance 7. Hyperthyroidism 8. Neurological disease 9. Probability of drug-induced hyperventilation (progestagens , aspirin, beta agonists)

Design outcomes

Primary

MeasureTime frameDescription
Trans-cutaneous Carbon Dioxide pressureduring hyperventilation testTrans-cutaneous Carbon Dioxide pressure measurements diagnostic of hyperventilation syndrome will be evaluated by comparing it with that of standard
End-tidal Carbon Dioxide partial pressureduring hyperventilation testEnd-tidal Carbon Dioxide partial pressure measurement. Consistency of the diagnostic conclusions reached by either test will be analyzed.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026